Product NDC: | 0006-3931 |
Proprietary Name: | ZIOPTAN |
Non Proprietary Name: | TAFLUPROST |
Active Ingredient(s): | .0045 mg/.3mL & nbsp; TAFLUPROST |
Administration Route(s): | OPHTHALMIC |
Dosage Form(s): | SOLUTION |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 0006-3931 |
Labeler Name: | Merck Sharp & Dohme Corp. |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | NDA202514 |
Marketing Category: | NDA |
Start Marketing Date: | 20120210 |
Package NDC: | 0006-3931-36 |
Package Description: | 1 POUCH in 1 CARTON (0006-3931-36) > 10 AMPULE in 1 POUCH > .3 mL in 1 AMPULE |
NDC Code | 0006-3931-36 |
Proprietary Name | ZIOPTAN |
Package Description | 1 POUCH in 1 CARTON (0006-3931-36) > 10 AMPULE in 1 POUCH > .3 mL in 1 AMPULE |
Product NDC | 0006-3931 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | TAFLUPROST |
Dosage Form Name | SOLUTION |
Route Name | OPHTHALMIC |
Start Marketing Date | 20120210 |
Marketing Category Name | NDA |
Labeler Name | Merck Sharp & Dohme Corp. |
Substance Name | TAFLUPROST |
Strength Number | .0045 |
Strength Unit | mg/.3mL |
Pharmaceutical Classes | Prostaglandin Analog [EPC],Prostaglandin Receptor Agonists [MoA],Increased Prostaglandin Activity [PE],Prostaglandins [Chemical/Ingredient] |